688 related articles for article (PubMed ID: 26341082)
1. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.
Bender RJ; Mac Gabhann F
BMC Syst Biol; 2015 Sep; 9():55. PubMed ID: 26341082
[TBL] [Abstract][Full Text] [Related]
2. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
3. Semaphorin-plexin signalling genes associated with human breast tumourigenesis.
Gabrovska PN; Smith RA; Tiang T; Weinstein SR; Haupt LM; Griffiths LR
Gene; 2011 Dec; 489(2):63-9. PubMed ID: 21925246
[TBL] [Abstract][Full Text] [Related]
4. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.
Liu H; Yang Y; Xiao J; Yang S; Liu Y; Kang W; Li X; Zhang F
Microvasc Res; 2014 May; 93():1-8. PubMed ID: 24603190
[TBL] [Abstract][Full Text] [Related]
5. Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas.
Osada R; Horiuchi A; Kikuchi N; Ohira S; Ota M; Katsuyama Y; Konishi I
Hum Pathol; 2006 Nov; 37(11):1414-25. PubMed ID: 17010410
[TBL] [Abstract][Full Text] [Related]
6. Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis.
Gaur P; Bielenberg DR; Samuel S; Bose D; Zhou Y; Gray MJ; Dallas NA; Fan F; Xia L; Lu J; Ellis LM
Clin Cancer Res; 2009 Nov; 15(22):6763-70. PubMed ID: 19887479
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF).
Ling MT; Lau TC; Zhou C; Chua CW; Kwok WK; Wang Q; Wang X; Wong YC
Carcinogenesis; 2005 Oct; 26(10):1668-76. PubMed ID: 15905202
[TBL] [Abstract][Full Text] [Related]
9. Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer.
Bender RJ; Mac Gabhann F
PLoS One; 2013; 8(5):e61788. PubMed ID: 23667446
[TBL] [Abstract][Full Text] [Related]
10. Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy.
Nordby Y; Andersen S; Richardsen E; Ness N; Al-Saad S; Melbø-Jørgensen C; Patel HR; Dønnem T; Busund LT; Bremnes RM
Prostate; 2015 Nov; 75(15):1682-93. PubMed ID: 26268996
[TBL] [Abstract][Full Text] [Related]
11. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues.
Pallares J; Rojo F; Iriarte J; Morote J; Armadans LI; de Torres I
Histol Histopathol; 2006 Aug; 21(8):857-65. PubMed ID: 16691538
[TBL] [Abstract][Full Text] [Related]
12. Semaphorin-4D (Sema-4D), the Plexin-B1 ligand, is involved in mouse ovary follicular development.
Regev A; Goldman S; Shalev E
Reprod Biol Endocrinol; 2007 Mar; 5():12. PubMed ID: 17376242
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
14. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA
Cancer Res; 2009 Jun; 69(11):4708-15. PubMed ID: 19487287
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1.
Krishnan B; Torti FM; Gallagher PE; Tallant EA
Prostate; 2013 Jan; 73(1):60-70. PubMed ID: 22644934
[TBL] [Abstract][Full Text] [Related]
16. The Semaphorin 4D-Plexin-B1-RhoA signaling axis recruits pericytes and regulates vascular permeability through endothelial production of PDGF-B and ANGPTL4.
Zhou H; Yang YH; Basile JR
Angiogenesis; 2014 Jan; 17(1):261-74. PubMed ID: 24114199
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model.
Melnyk O; Zimmerman M; Kim KJ; Shuman M
J Urol; 1999 Mar; 161(3):960-3. PubMed ID: 10022734
[TBL] [Abstract][Full Text] [Related]
18. Recombinant semaphorin 6A-1 ectodomain inhibits in vivo growth factor and tumor cell line-induced angiogenesis.
Dhanabal M; Wu F; Alvarez E; McQueeney KD; Jeffers M; MacDougall J; Boldog FL; Hackett C; Shenoy S; Khramtsov N; Weiner J; Lichenstein HS; LaRochelle WJ
Cancer Biol Ther; 2005 Jun; 4(6):659-68. PubMed ID: 15917651
[TBL] [Abstract][Full Text] [Related]
19. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.
Lohela M; Bry M; Tammela T; Alitalo K
Curr Opin Cell Biol; 2009 Apr; 21(2):154-65. PubMed ID: 19230644
[TBL] [Abstract][Full Text] [Related]
20. MiR-130b/TNF-α/NF-κB/VEGFA loop inhibits prostate cancer angiogenesis.
Mu HQ; He YH; Wang SB; Yang S; Wang YJ; Nan CJ; Bao YF; Xie QP; Chen YH
Clin Transl Oncol; 2020 Jan; 22(1):111-121. PubMed ID: 31667686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
